Use access key #2 to skip to page content.
  • S&P 500: 1,070.52
  • Change: 1.30%
$3.09 0.01 (0.32%)
2/9/2010 4:00 PM

ArQule, Inc. (ARQL)

CAPS Rating:
**

A clinical-stage biotechnology company, engaged in the research and development of cancer therapeutics. Its mission is to research, develop and commercialize targeted cancer drugs with reduced toxicities compared to conventional cancer chemotherapeutics.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating ARQL

Add Stock to Watchlist

What the Community Thinks

Total Members

139 Outperforms
16 Underperforms
 

All-Stars

44 Outperforms
9 Underperforms
 

Wall Street

11 Outperforms
0 Underperforms
 

Members bullish on ARQL are also bullish on:

Members bearish on ARQL are also bearish on:

Ticker Tags

Aggressive Growth (860), Biotechnology (220), Distressed (1597), Micro Cap (4701), Defensive (1457), Growth (1902), Healthcare (711), Rule Breakers Universe (125)
Suggest a tag

ArQule, Inc. At A Glance

Current Price: $3.09
Last Trade Time: 2/9/2010 4:00 PM
Open: $0.00
Previous Close: $3.08
Daily Range: $3.06 - $3.13
52-Week Range: $2.62 - $6.38
Volume: 118,487
Market Cap: $138.09M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

ARQL VS S&P 500 (SPY)

News & Discussion Boards

Top Bull Pitch

Recs

2

ArQule, Inc. (ARQL)

Avatar zzlangerhans (99.64) Submitted: 11/27/09 10:26 AM

Arqule is expecting phase II data for ARQ197 in NSCLC and MiT as well as phase I data for ARQ621 Eg5 inhibitor in early 2010. Enrollment has also begun for phase II trial of ARQ197 in hepatoma. The one year low was 2.76 in March. Company has substantial cash and stock will almost certainly rise prio...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

1

ArQule, Inc. (ARQL)

Avatar pajeth (< 20) Submitted: 2/19/07 7:59 AM

Carefully watching this stock, hoping for some positive news.

Replies: 0 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 20 :   1 2 3 4 Next »

Recs

2

 (ARQL)

Avatar zzlangerhans (99.64) Submitted: 11/27/09 10:26 AM : Outperform Start Price: $3.50 ARQL Score: -9.61

Arqule is expecting phase II data for ARQ197 in NSCLC and MiT as well as phase I data for ARQ621 Eg5 inhibitor in early 2010. Enrollment has also begun for phase II trial of ARQ197 in hepatoma. The one year low was 2.76 in March. Company has substantial cash and stock will almost certainly rise prior to phase II data release. I've been a skeptic before, but at these prices I'm a Qulio.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ARQL)

Avatar wakoma (52.40) Submitted: 9/29/08 7:46 AM : Outperform Start Price: $3.15 ARQL Score: 5.79

Bought based on feedback from a couple of friends in the oncology industry. Small position. yrs away from knowing the outcome. Some smart money likes what they see. Who knows. Pretty much dead money for the near term

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ARQL)

Avatar Dapperatom (< 20) Submitted: 5/14/08 1:54 PM : Outperform Start Price: $4.23 ARQL Score: -5.23

I like the below $10 price and its potential for a good return.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ARQL)

Avatar spicebyr (88.92) Submitted: 4/27/08 9:42 AM : Outperform Start Price: $3.84 ARQL Score: 0.94

This issue has too many LARGE investment banks/investors putting $$$ into it. Currently (late April 2008) it has been beaten to a point where an entry at this level will "probably" provide 100% ROI. Everyone is responsible for their own due diligence. This is one that has GREAT potential!!!

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ARQL)

Avatar Fundzrlow (< 20) Submitted: 4/24/08 11:40 AM : Outperform Start Price: $3.85 ARQL Score: -0.19

I think this an upcoming stock, although it fluctuates it is a strong stock.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 20 :   1 2 3 4 Next »

Wall Street

Results 1 - 11 of 11  

picks per page. CHANGE Expand All Pitches

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackUBS 87.99 10/14/09 Outperform NS $4.35-28.97%-0.16%-28.81
TrackOppenheimer 81.36 12/01/08 Outperform NS $3.29-6.08%+25.71%-31.79
TrackBofASec 94.61 09/03/08 Outperform NS $3.44-10.17%-13.50%+3.33
TrackEveillard 93.31 09/30/07 Outperform NS $7.13-56.66%-26.38%-30.29 Toggle the visibility of 60-Second Pitch and replies
TrackLazardCapit < 20 09/14/07 Outperform NS $7.68-59.77%-23.94%-35.83
TrackNeedham 67.64 06/01/07 Outperform NS $9.37-67.02%-26.43%-40.60
TrackCantorFitz 31.61 05/22/07 Outperform NS $9.46-67.34%-25.77%-41.57
TrackStanfordRes 85.54 05/03/07 Outperform NS $9.11-66.08%-24.56%-41.52
TrackFortisBank 83.59 04/30/07 Outperform NS $9.28-66.70%-24.24%-42.46
TrackLeerinkSwan 92.83 04/04/07 Outperform NS $7.74-60.08%-21.09%-38.98
TrackWRHambrecht 64.18 03/08/07 Outperform NS $6.52-52.61%-19.34%-33.27

Results 1 - 11 of 11  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

EQWEBD02 234ms